# REGULARLY SCHEDULED SERIES ANNOUNCEMENT

# **New and Emerging Therapies in IBD**

Date/Time: 9/27/2024 2:00:00 PM Activity ID: 19791

**Location:** AdventHealth HOV

**Topic:** This talk will go over new therapies compounding the field of IBD and help learners understand

their benefits and limitations which is crucial to properly managing disease.

## **Objectives:**

At the conclusion of this activity, the participant will be able to:

1 Discuss current IBD portfolio.

2 Discuss current trends towards precision medicine.

**Accreditation:** ACPE Universal Activity Number (UAN): Technician:

## American Medical Association (AMA)

AdventHealth Orlando is accredited by the Florida Medical Association (FMA) to provide continuing medical education for physicians.

AdventHealth Orlando designates this live activity for a maximum of *AMA PRA Category 1 Credit(s)* $^{\text{TM}}$ . Physicians should only claim the credit commensurate with the extent of their participation in the activity.

#### Florida Board of Nursing

The Florida Board of Nursing accepts a CE activity that has been approved by an agency that regulates a healthcare profession or discipline in Florida or another jurisdiction.

#### **Other Healthcare Professionals**

Other healthcare professionals who participate in this activity may submit their statement of participation to their appropriate accrediting organizations or state boards for consideration of credit. Participants are responsible for determining whether this activity meets the requirements for acceptable continuing education.

### **Disclosures:**

AdventHealth Orlando CME adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

The planners and faculty of this series have disclosed the following financial relationship(s) with ineligible companies/commercial interests:

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Mariam Naveed, MD	Course Director, Faculty	Nothing to disclose - 02/08/2024
Karen L. Gonzalez, BS	Activity Coordinator	Nothing to disclose - 02/01/2024
Jami A. Kinnucan, MD	Faculty	Consulting Fee-Abbvie   Consulting Fee-



		UCB Consulting Fee-Fresinius
		kabi Consulting Fee-Takeda
		Pharmaceuticals, Inc.   Consulting Fee-
		Johnson and Johnson   Consulting Fee-
		BMS   Consulting Fee-Pfizer, Inc
		02/12/2024
Mohammad M. Asfari, MD	Co-Director	Nothing to disclose - 02/08/2024
Jennifer Seminerio-Diehl, MD	Faculty	Consulting Fee-Abbvie   Consulting Fee-
		Johnson and Johnson   Consulting Fee-
		Bristol-Myers Squibb Speakers Bureau-
		Pfizer, Inc.   Consulting Fee-Takeda
		Pharmaceuticals, Inc.   Consulting Fee-
		Lilly - 09/24/2024